Provided by Tiger Trade Technology Pte. Ltd.

FOSUN PHARMA

17.150
+0.0100.06%
Volume:3.62M
Turnover:62.09M
Market Cap:45.48B
PE:11.54
High:17.290
Open:16.880
Low:16.880
Close:17.140
52wk High:27.920
52wk Low:14.505
Shares:2.65B
HK Float Shares:534.00M
Volume Ratio:0.67
T/O Rate:0.68%
Dividend:0.46
Dividend Rate:2.66%
EPS(LYR):1.486
ROE:6.95%
ROA:1.40%
PB:0.80
PE(LYR):11.54
PS:0.91

Loading ...

FOSUN PHARMA's Venlafaxine Hydrochloride Extended-Release Tablets Receive Market Approval

Stock News
·
May 08

Shanghai Fosun Pharma - Drug Registration Application for Venlafaxine Hydrochloride Sustained-Release Tablets Approved by China's Nmpa

THOMSON REUTERS
·
May 08

Sinopharm Group Stock Sheds 1.6% in Hong Kong

Dow Jones
·
May 08

Leadership Reshuffle Sweeps Pharmaceutical Sector: Hengrui, Fosun, AstraZeneca, Pfizer Among Key Players

Deep News
·
May 07

Shanghai Fosun Pharma - Drug Registration Application for Sodium Nitroprusside Injection Approved by Nmpa

THOMSON REUTERS
·
Apr 30

Fosun Pharma Maintains Stable Share Base in April; 0% New Issuance, Public Float Compliant

Bulletin Express
·
Apr 30

FOSUN PHARMA Subsidiary Receives Regulatory Approval for Sodium Nitroprusside Injection

Stock News
·
Apr 30

Fosun Pharmaceutical Reports 14% Higher Profit in Q1

MT Newswires Live
·
Apr 29

Press Release: Fosun Pharma Announces Q1 2026 Results: Net Profit Attributable to Shareholders After Deducting Non-Recurring Gains and Losses Increased by 21.96% YoY, With Strong Pipeline Execution

Dow Jones
·
Apr 28

Morgan Stanley Raises Fosun Pharma's Revenue Forecast, Sets HK$32 Target with "Overweight" Rating

Stock News
·
Apr 22

FOSUN PHARMA’s 2025 ESG Report Highlights: AA MSCI Rating, RMB 5.91 Billion R&D Spend, and Strong Green, Social Commitments

Bulletin Express
·
Apr 21

Fosun Pharma Releases 2025 ESG and Sustainability Report

Bulletin Express
·
Apr 21

复星医药2025年报:净利润同比增至33.71亿元,业务与治理结构持续优化

Bulletin Express
·
Apr 21

FOSUN PHARMA Announces Release of 2025 Annual Report and Updates Shareholder Communication Arrangements

Bulletin Express
·
Apr 21

BRIEF-Shanghai Fosun Pharma Unit Received Approval From NMPA

Reuters
·
Apr 14

Fosun Pharma Unit Gets China Nod for Amyloidosis Drug Trial

MT Newswires Live
·
Apr 14

Fosun Pharma receives NMPA green light for Phase I/II trials of dual-target CAR-T therapy FKC289

Bulletin Express
·
Apr 14

Shanghai Fosun Pharma - Unit Received Approval From Nmpa for Phase I/Ii Clinical Trial of Fkc289 Injection

THOMSON REUTERS
·
Apr 14

FOSUN PHARMA Subsidiary Receives Approval for Phase I Trial of HLX05-N Cancer Treatment

Stock News
·
Apr 14

Hong Kong Market Announcement Highlights: VGT Launches IPO with CPE Rosewood and Janchor Fund as Cornerstone Investors

Stock News
·
Apr 13